Overexpression of the ERBB2 gene, linked to genomic and transcriptional amplifications, is a poor prognosis indicator in 25% to 30% of breast cancers. In contrast to some well-documented genomic amplifications, molecular mechanisms leading to ERBB2 transcriptional overexpression remain poorly characterized. Gene expression analyses of breast cancer have characterized distinct transcriptional signatures allowing a molecular classification of breast carcinoma. Coexpression of the ERBB2 and GATA4 genes was originally observed in tumors. Both genes are essential for cardiovascular development and GATA4 has been proposed to control the transcription of critical genes for the differentiation and the function of myocardium. We determined that ERBB2-targeted small interfering RNA repressed both ERBB2 and GATA4 genes, whereas GATA4-targeted small interfering RNA repressed GATA4 and activated ERBB2 transcription. Transfected GATA4-expressing construct repressed ERBB2 promoter. Phylogenetic foot printing revealed multiple putative GATA4 binding sites conserved in mammals within the ERBB2 promoter region. Chromatin immunoprecipitation showed that GATA4 binds specifically to several ERBB2 gene noncoding regions. Electrophoretic mobility shift assay revealed GATA4 binding to a well-conserved consensus motif. Site-directed mutagenesis confirmed the role of this new regulatory element for the activity of the ERBB2 gene enhancer. In agreement with a repressor role of GATA4 on ERBB2 gene expression balanced by ERBB2 activation of the GATA4 gene, a negative correlation between the relative levels of ERBB2 and GATA4 mRNA was observed in breast cancer cell lines and breast tumor samples. We propose that the negative feedback loop linking ERBB2 and GATA4 plays a role in the transcriptional dysregulation of ERBB2 gene expression in breast cancer. (Mol Cancer Res 2009;7(3):402 -14) 
Introduction
The ERBB2 gene encodes a tyrosine kinase receptor belonging to the epidermal growth factor receptor family (1) . Amplification and overexpression of this receptor is a poor prognosis indicator observed in 25% to 30% of breast cancers but also in other types of cancer with variable proportions (2) . Its detection might also predict resistance to chemotherapy. In breast cancer with ERBB2 amplification, current treatments include humanized monoclonal antibody trastuzumab (Herceptin) directed against ERBB2, which blocks the activity of the receptor by poorly defined mechanisms. However, resistance to trastuzumab is frequent and this drug can trigger some cardiotoxicity (3) (4) (5) .
Overexpression of ERBB2 was originally attributed to genomic amplification, but it appeared rapidly that increased transcription was observed in all analyzed tumor cells (6) . These observations indicate that overexpression at the transcriptional level can precede gene amplification and contribute to the severity of the disease (7) . More recently, several reports showed that various transcriptional and post-transcriptional mechanisms contribute to increased levels of ERBB2 transcript and protein in cancer cells (8) (9) (10) . In this context, a precise and complete definition of the regulatory elements and their cognate transcription factors that control ERBB2 gene transcription is a major challenge.
ERBB2 gene transcription is under the control of at least two promoters separated by 12 kb (11) . Although the distal promoter remains poorly defined, several regulatory elements have been characterized within the proximal promoter and its 5 ¶-flanking sequence up to the 6 kb upstream of the major transcription start site (TSS; refs. 8, 12-16; Fig. 1A) . A set of studies suggest that several associated transactivators, or transrepressors such as FOXP3 and PEA3 (10, 17) , are involved in the increased transcription of the ERBB2 gene in breast cancer cells (8, (12) (13) (14) (18) (19) (20) (21) . Among the sequence-specific transcription factors bound specifically to the proximal ERBB2 promoter, only AP-2 and ETS factor family members are required for a maximal promoter activity in transient transfection assays and are associated with ERBB2 gene overexpression in breast cancers (7, 12, 22, 23) . It was also proposed that the regulatory regions of the ERBB2 gene involved in its overexpression in epithelial breast cancer cells might be different from those contributing to its overexpression in colon and ovarian cancers (8, 9) .
Gene expression analyses of breast cancers with various pathophysiologic and/or prognostic features have characterized several sets of coregulated genes that define transcriptional signatures, allowing a precise molecular classification of breast cancers in subtypes (24) . In one study, the gene encoding the transcription factor GATA4 was identified as one of the 29 overexpressed genes differentially expressed in tumors associated with ERBB2 overexpression (24, 25) . Interestingly, ERBB2 and GATA4 are essential for cardiovascular development (26) (27) (28) and it has been proposed that GATA4 controls the transcription of critical genes for both differentiation and function of the myocardium. The transcriptional activity of GATA4 is activated via the mitogen-activated protein kinase pathway in cardiomyocytes (29) and the ERBB2 receptor triggers several transduction pathways including the mitogenactivated protein kinase pathway (2) . However, no direct functional link has been established thus far between ERBB2 and GATA4. Consequently, we have hypothesized the existence of a direct functional interaction between these two major regulators of mammalian development and cell biology. Using a combination of functional and interaction studies, we show here that the ERBB2 gene is a direct target of GATA4. We propose that the GATA4 gene is activated by the ERBB2 receptor, whereas the ERBB2 gene is repressed by the transcription factor GATA4 through a negative feedback regulatory loop.
Results

GATA4 Can Repress ERBB2, Whereas ERBB2 Can Activate GATA4
To investigate the functional relations between ERBB2 and GATA4, RNA interference (RNAi) assays were carried out in the breast cancer cell line BT-474, which overexpresses both ERBB2 and GATA4. A 10-and 2-fold decrease of ERBB2 and GATA4 RNA levels were observed, respectively, when human ERBB2 Stealth select RNAi (Invitrogen) were transiently transfected in BT-474 cells (Fig. 2A) . Immunoblotting of lysates from small interfering RNA (siRNA)-transfected cells Fig. 3 (13) . Numbering relative to RefSeq entry NM_004448 differs from the original report, which refers to an alternative TSS (57) confirmed the abolition of the ERBB2-specific signal in the presence of ERBB2 siRNA and the dramatic reduction of GATA4 compared with matched control (Fig. 2B, lanes 1  and 3) . In contrast, GATA4 Stealth select RNAi induced a 2.5-fold increase of ERBB2 RNA level while producing a 2-fold inhibition of GATA4 RNA (Fig. 2C) . Accordingly, immunoblotting of lysates from GATA4 siRNA-transfected cells revealed a significant decrease of GATA4 protein level, whereas siRNA treatment significantly increased ERBB2 protein level (Fig. 2B, lane 2) . Neither set of Stealth select RNAi affected the expression of the gene coding for h-tubulin and TBP ( Fig. 2B ; data not shown). Because FOXP3 has been recently identified as a major negative regulator of ERBB2 gene expression in mammary tumors (10), we wondered whether this transcription factor of the forkhead family might be involved in GATA4-dependent ERBB2 gene repression. As shown in Fig. 2D , GATA4 siRNA had no effect on FOXP3 gene expression, whereas ERBB2 siRNA induced a 3-fold reduction of FOXP3 RNA. These results excluded apparently the hypothesis of an indirect inhibition of the ERBB2 gene by GATA4 via the repression of the FOXP3 gene transcription and added FOXP3 in the list of transcription factors activated by ERBB2 signaling (30) . Altogether, these results suggested the presence of a regulatory loop linking the ERBB2 and GATA4 genes in BT-474 cells where GATA4 can directly repress ERBB2 and ERBB2 can activate GATA4.
GATA4 and ERBB2 mRNA Expression Levels Are Negatively Correlated
Results obtained with ERBB2 and GATA4 siRNA were unexpected when one considers our original observation based on transcriptome analysis using human cDNA microarrays. We have indeed reported previously a transcriptional signature including correlated ERBB2 and GATA4 overexpression in a set of breast cancer cell lines and tumor samples (25) . Therefore, real-time quantitative reverse transcription-PCR (qRT-PCR) analyses were done to determine the relative levels of ERBB2 and GATA4 mRNA in 17 breast cancer cell lines and 17 breast carcinoma samples. The normal breast epithelial cell line HME-1 was used as a reference to measure the relative gene expression (RGE) of both genes. ERBB2 RGE was negatively correlated to GATA4 RGE with a Spearman rank correlation coefficient equal to -0.515 in breast cancer cell lines (Fig. 3A) FIGURE 2. ERBB2 activates GATA4 and GATA4 represses ERBB2 in BT-474 cells. A. Effect of transfection of ERBB2 siRNA on GATA4 and ERBB2 expression. Relative GATA4 and ERBB2 RNA levels on treatment with either human ERBB2 Stealth RNAi (HSS103333 and HSS103334) or matched negative controls (Med and Lo GC, respectively) determined qRT-PCR (empty and gray columns , respectively). Y axis, RGE normalized against TBP levels as described in Materials and Methods. Mean F SE of 6 independent assays. B. ERBB2 and GATA4 protein levels determined by immunoblotting of cell lysates treated by ERBB2 (lane 1), GATA4 (lane 2), or control (lane 3 ) siRNA using GATA4 and ERBB2 antibodies. The amount of h-tubulin was used as loading control. C. Effect of transfection of GATA4 siRNA on GATA4 and ERBB2 expression. Relative GATA4 and ERBB2 RNA levels on treatment with either human ERBB2 Stealth RNAi (HSS104005 and HSS104007) or matched negative controls (Lo and Med GC, respectively) determined by qRT-PCR (empty and gray columns , respectively). Y axis, RGE normalized against TBP level as described in Materials and Methods. Mean F SE of 12 independent assays. D. Effect of transfection of GATA4 and ERBB2 siRNA on FOXP3 gene expression. RNA samples tested were the same as used in A and C.
and -0.517 in tumor samples (Fig. 3B ). These significant negative correlations (P = 0.035 and 0.034, respectively) were in agreement with the increased level of ERBB2 when GATA4 was repressed by specific siRNA. They are also in agreement with the hypothesis of a negative feedback loop of regulation linking ERBB2 and GATA4. The discrepancy with our original cDNA microarray observations (25) is most probably due to the difference in sensitivity between the two methods employed. It is well documented indeed that qRT-PCR is more sensitive in detecting a relative change than microarrays, which underestimate sometimes dramatically the actual expression change (31, 32) . This is particularly true for the low expressed genes such as GATA4 in our experiments. Consequently, it was not a posteriori unexpected to observe a coexpression of ERBB2 and GATA4 because ERBB2 activates GATA4, although it was not possible to determine precisely their relative changes using DNA microarrays.
GATA4 Represses the Transcriptional Activity of the Human ERBB2 Gene Promoter and Its 5 ¶-Flanking Sequences
To evaluate whether GATA4 can directly act on ERBB2 gene transcription, we used luciferase gene reporter vectors containing ERBB2 enhancer/promoter fragments of increasing size ( Fig. 1B ; ref. 33 ) and a mammalian expression vector for human GATA4 (34) . The series of ERBB2 enhancer/promoter fragments were first transiently transfected alone in two breast cancer cell lines with ERBB2 gene amplification, BT-474 (RGE ERBB2 = 25 and GATA4 = 304) and HCC-1954 (RGE ERBB2 = 22 and GATA4 = 0.01), and one without, HCC-1806 (RGE ERBB2 = 0.05 and GATA4 = 126). As shown in Fig. 4A , the p3798 plasmid sustained the strongest luciferase activity normalized to that sustained by p215 containing a human ERBB2 minimal promoter fragment, which has been shown to direct similar activity in a set of related breast cancer cell lines revealed by qRT-PCR. X and y axes, RGE levels of ERBB2 and GATA4 RNA, respectively, in breast cancer cell lines or tumor samples normalized to the levels of ERBB2 and GATA4 RNA measured in the normal breast epithelial cells HME-1 as described in Materials and Methods. Closed lozenges, normalized gene expression values determined for each cell line as described in Materials and Methods. Gray line, linear regression of Pearson. The coefficient of correlation r was determined and its statistical significance was tested using the nonparametric Spearman rank correlation test.
ERBB2/GATA4 Regulatory Loop in Breast Cancer Cells
Mol Cancer Res 2009;7(3). March 2009 (13) . However, our results differ from original reports (13, 33) where p3798 displayed a very weak transcriptional activity when compared with p716 or p6007 in the same breast cancer cell line. Each luciferase vector was sequenced to eliminate any mix-up (data not shown) and observations were highly reproducible in at least three independent experiments. A difference linked to the normalization used for our assays was also excluded (dual luciferase assay versus protein concentration). It shall also be noted that some significant variations using the same set of vectors were presented in at least two reports (compare Fig. 2 in 33 and Fig. 1 in 13 ), but there is no clear explanation at this stage for these discrepancies.
When the set of ERBB2 enhancer/promoter fragments were cotransfected together with a GATA4 expression vector in BT-474 cells, the corresponding activities were dramatically reduced when compared with the activities observed in the absence of artificially overexpressed GATA4. This repressive effect was observed on all constructs, except p215, as well as on the unrelated pNF-nB-Luc control plasmid ( Fig. 4B and C). The same repressive effect was also observed when the cotransfection was done in HCC-1954 cells, which do not express GATA4 (Fig. 4D ). No effect was observed when the cotransfection assays were done in the ERBB2-negative HCC-1806 cells, which overexpress GATA4 (RGE = 126). Most probably, the strong endogenous GATA4-negative signal in this cell line precluded any effect of further overexpression. Interestingly, an even higher GATA4 overexpression was detected in BT-474 cells (RGE = 304), although ERBB2 was significantly active, indicating the presence of stronger positive signals that stimulated ERBB2 gene transcription in this breast cancer cell line.
Altogether, our results suggested that GATA4 can act directly on several locations within the ERBB2 promoter 5 ¶-flanking sequence from nucleotides -5949 to -156 relative to the major TSS characterized in the RefSeq record NM_004448.
Human ERBB2 Gene Contains Several Conserved Putative GATA Binding Sites
To determine whether the 5 ¶-flanking sequence of the ERBB2 gene contains putative binding sites for members of the GATA transcription factor family, a comparison between human and mouse gene sequences was done combined with a search for GATA binding sites. Eight conserved regions were characterized by analysis of the corresponding sequences of the human and murine ERBB2 genes using the online software PipMaker 6 (Fig. 5A ). Several potential binding sites for GATA factors were identified in seven of eight conserved regions by a search combining several methods (consensus WGATAR, Nucleotide Position Weight Matrix, etc.). Interestingly, the nucleotide [-156, +100] region, corresponding to the minimal promoter region included in the p215 construct, did not contain any identifiable GATA consensus site in agreement with the absence of effect of overexpressed GATA4 in transient transfection assay. Similarly, the nucleotide [-5446, -5065] CR3 region did not contain any GATA consensus site, whereas six GATA putative binding sites were found within CR7 located at nucleotide [-561, +310].
GATA4 Is Bound In vivo to Several Locations in the ERBB2 Gene Enhancer/Promoter Region
In vivo recruitment of GATA4 was tested by chromatin immunoprecipitation assay in BT-474 cells. After cross-linking and sonication, the chromatin extract was immunoprecipitated by a commercial, GATA4-specific mouse monoclonal antibody and the corresponding DNA fragments were purified as described previously (35) . Portions of the seven characterized conserved regions containing putative GATA binding sites plus GATA-less CR3 were amplified by PCR using specific primer pairs (Table 1 ) and quantified using SYBR Green chemistry and a Light Cycler 2 (Roche Diagnostics). As illustrated in Fig. 5B and C, several conserved regions were bound in vivo by GATA4 including the proximal regulatory promoter region included in CR7 and, to a less extent, CR4, CR5, and CR8. As expected, no significant recruitment of GATA4 was observed within CR3 devoid of any GATA consensus site but also in CR1, CR2 and CR6, notwithstanding the presence of bona fide GATA consensus sites. This confirms that not all consensus binding sites are accessible in vivo for the recruitment of a given sequence-specific transcription factor. Altogether, these results identified in vivo binding of GATA4 in several locations within the ERBB2 gene enhancer/promoter region, in accordance with a direct role of this transcription factor in the regulation of human ERBB2 gene transcription.
GATA4 Represses the ERBB2 Gene Enhancer/Promoter through a Positive Regulatory Element
Although chromatin immunoprecipitation assays revealed in vivo recruitment of GATA4 at several locations within the Table 1 . B. Quantitative chromatin immunoprecipitation assays done using a GATA4 monoclonal antibody as described in Materials and Methods. Mean F SE of 3 to 6 independent experiments. C. Representative semiquantitative chromatin immunoprecipitation assays done with the GATA4-less CR3 region and the GATA4 -containing CR7 region using either a GATA4 monoclonal antibody or a matched IgG 2a control as indicated below the lanes.
ERBB2 gene enhancer promoter, they cannot define which putative GATA binding sites are functional. For example, four GATA potential binding sites were identified within the 338-bp fragment nucleotide [-525, -187] amplified by PCR (Fig. 6A ). Among these four putative binding sites, the WGATAR motif nucleotide [-286, -281] was strictly conserved between human and mouse. In addition, this GATA consensus was almost identical to a functional GATA4-specific binding site identified in the human IL-5 gene promoter ( Fig. 5B; ref. 36 ). Therefore, we designed a 21-bp oligonucleotide probe covering this WGATAR motif to perform electrophoretic mobility shift assays (EMSA) using nuclear extracts from BT-474 cells (Fig. 6B) . Similar migration profiles were observed with both IL-5 and ERBB2 GATA wild-type probes including five major retarded protein-DNA complexes (Fig. 6C, lane 2; data not shown). Competition using an excess of unlabeled wild-type doublestranded oligonucleotides abolished the three C1, C2, and C3 complexes (Fig. 6C, lanes 3 and 5) , which were not affected by the corresponding mutant competitors (Fig. 6C, lanes 4 and 6) . This showed that the three C1, C2, and C3 complexes are specific to the WGATAR motif present in the ERBB2 GATA probe.
The reaction mixtures were incubated with antibodies directed against five members of the GATA family (GATA1-4 and GATA6) to determine which of these factors may contribute to the formation of the specific protein-DNA complexes. As shown in Fig. 6D (lane 7) , only the GATA4-specific antibodies retarded migration of C2 complex observed with the wild-type ERBB2 GATA probe. Accordingly, only GATA4 antibodies slowed down the migration of the corresponding complex detected using the wild-type IL-5 GATA probe (Fig. 6D, lane 10 ; data not shown).
To determine whether the bona fide GATA4 binding site at nucleotide [-286, -281 ] is transcriptionally activated, this site was abrogated by site-directed mutagenesis in the luciferase construct p3798 (Fig. 1C) . Wild-type and mutated constructs were then transiently transfected in BT-474. As illustrated in Fig. 6E , the transcriptional activity was dramatically reduced in the p3798 Mut construct. The lack of further repression in the presence of coexpressed GATA4 evidenced that an intact WGATAR motif is required for GATA4-mediated repression of the ERBB2 enhancer/promoter region. No significant differences were observed when using a low-activity p716 wild-type and p716 Mut plasmids (data not shown).
Altogether, these results strongly indicate that GATA4 mediates ERBB2 down-regulation through a bona fide WGATAR motif embedded in a positive regulatory element required for elevated expression of the ERBB2 gene.
Discussion
The molecular mechanisms leading to ERBB2 overexpression in human cancers remain poorly characterized, except for the well-documented genomic amplification. However, ERBB2 gene amplification alone is apparently not sufficient to explain all cases of RNA and protein overexpression (6) because a significant proportion of human cancers with increased expression of ERBB2 do not exhibit gene amplification (37) (38) (39) . There are converging lines of evidence that an increase of ERBB2 mRNA levels per gene copy depends on ERBB2 gene transcription. Several regulatory elements located near the major TSS of the ERBB2 gene promoter have been characterized previously as well as some more distal elements up to 6 kb in the 5 ¶-flanking sequence and in the ERBB2 gene first intron (8, (12) (13) (14) (18) (19) (20) (21) . Altogether, data suggested their involvement in the increased transcription of the ERBB2 gene observed in breast cancer cells. Two of the cognate transcription factors associated with the previously characterized regulatory elements have been identified as negative regulators of ERBB2 expression in breast cancer. The ETS DNA-binding protein PEA3 targets specifically a DNA motif on the ERBB2 gene promoter and down-regulates its promoter activity, but there is no clear evidence that genetic lesions of PEA3 can cause ERBB2 overexpression (17) . The transcription factor FOXP3 recently characterized as a X-linked breast cancer tumor suppressor in mice and humans represses transcription of the ERBB2 gene via interaction with forkhead DNA-binding motifs in the ERBB2 promoter (10) . Although the functional relationships between these negative and positive transacting factors remain largely unexplored, these results illustrate altogether the complexity of ERBB2 gene transcriptional regulation that requires further investigation. In this context, we provide here evidence that the transcription factor GATA4 can also act as a transcriptional repressor of the ERBB2 gene in breast cancer cells through its direct binding to ERBB2 regulatory sequences. Interestingly, the three best characterized transrepressors of the ERBB2 gene (FOXP3, PEA3, and GATA4) appear to act through three positive regulatory elements embedding their cognate binding sites (see Fig. 3E and G in ref. 10 , Fig. 3A in ref. 17 , and Fig. 6D and E) . This suggests the intervention of unidentified transactivators acting on these bifunctional regulatory elements. Accordingly, our EMSA has evidenced the presence of three specific protein-DNA complexes, whereas only the C2 complex was displaced by GATA4-specific antibodies, suggesting the presence of other sequence-specific transcription 3 and 9) or presence of GATA-specific antibodies (lanes 4-8 and 10) before addition of the radiolabeled ERBB2-GATA4 and IL5-GATA4 -Wt probes (lanes 1-8 and 9-10, respectively) as indicated above the lanes. Lanes 1 and 2, migration of the radiolabeled probe ERBB2-GATA4 -Wt without nuclear cell extract in the absence or presence of GATA4 monoclonal antibody. Right, migration of the GATA4-containing complex C2 and its shifted position in the presence of GATA4 antibody (closed and open arrowheads , respectively). E.
Luciferase reporter gene activity driven by either wild-type or a mutated p3798 construct (Fig. 1C) transiently transfected in BT-474 cells in absence or presence of overexpressed GATA4. Percentage F SE luciferase activity relative to the activity of the p3798T without overexpressed GATA4 defined as 100.
factors. The elucidation of the underlying molecular mechanisms requires further investigation to identify the transactivators associated to these bifunctional regulatory elements and their role in the dysregulations of ERBB2 in cancer cells.
Our siRNA assays excluded an indirect effect of GATA4 via a putative action on the expression of the FOXP3 gene because GATA4 siRNA did not affect significantly FOXP3 RNA levels. We also wondered whether cofactors of the FOG family that modulate the activity of the GATA transcription factors in mammals (40) might be involved. Although a role of the GATA4 partner FOG2/ZFPM2 (41) appears excluded in BT-474 cell line, which does not overexpress the corresponding gene (data not shown), an involvement of FOG1/ZFPM1 in GATA4-dependent repression of ERBB2 is a worth investigating possibility (42) .
A repressor role for GATA4 is in agreement with previous observations on this transcription factor, which can act as both a transcriptional activator and a repressor depending on various factors such as the target gene, the cell type, the interactions with other sequence-specific transcription factors, or even the localization of its binding site relative to the core promoter. For example, GATA4 activates the gene coding for P450c17 by direct interaction with SP1 (34), the Grp78/BiP gene in cooperation with ATF6 in embryonic heart (43), as well as the IL-5 gene in T lymphocytes (36) . In contrast, GATA4 acts as a repressor of the a2(I) collagen (COL1A2) via its binding to both proximal promoter and intronic elements (44, 45) . Furthermore, GATA4 binds two sites of the FGF3 promoter acting as positive and negative regulatory elements (46) .
Inhibition of GATA4 and FOXP3 by ERBB2-targeted siRNA enlarges the list of transcription factors involved in ERBB2 signaling, which already include multiple factors such as FOS/ JUN, EGR1, MYC, ELK, and SP1 (30) . Altogether, these results and our own observations show that the transcriptional control of ERBB2 is much more complex than expected and require further detailed investigation before designing any credible or risk-limited ''transcriptional'' therapy directed against either ERBB2 regulatory elements and/or their cognate sequence-specific transcription factors.
GATA4 transcriptional activity is activated by the mitogenactivated protein kinase pathway in cardiomyocytes (29) and the ERBB family triggers several signaling pathways including this pathway (2) . Although the activation of GATA4 by the mitogen-activated protein kinase pathway subsequent to ERBB2 overexpression in breast cancer cells requires further exploration, it was reported that GATA4 gene expression is induced by ERBB4 (47) . Because GATA4 negatively regulates ERBB2 expression, an ERBB2/ERBB4/GATA4 regulatory loop might explain why co-overexpression of ERBB4 with ERBB2 in mammary carcinoma is associated with a more favorable clinical outcome than overexpression of ERBB2 alone (48) . Similarly, the regulatory networks that associate the multiple transcription factors activated by the ERBB2 receptor and the ERBB2 gene itself need extensive investigation to determine which are direct targets and what are the putative regulatory loops linking these genes.
Trastuzumab, a humanized anti-ERBB2 antibody, is a major therapeutic agent for patients with overexpressed ERBB2 receptor on cancer cells. This treatment blocks the activity of the receptor by multiple and partially defined mechanisms, but resistance to trastuzumab is frequent (3). Some secondary cardiac effects have also been observed with this agent and more particularly when associated with anthracyclines (4, 5, 49) . Studies in animals and cell culture have provided some insight into the mechanisms of trastuzumab-induced decrease of cardiac contractile function (for review, see ref. 49) . Gene targeting studies and conditional deletion of ERBB2 in mice have shown that ERBB2 is essential for maintenance of normal cardiac structure and function. Collectively, published data suggest that one role of ERBB2/4 signaling is to dynamically regulate sarcomere structure. In contrast, overexpression of the transcription factor GATA4, known to be important in the regulation of cardiac sarcomeric protein expression, protects the heart against anthracycline toxicity in a mouse model (50) . It remains to establish whether the ERBB2/GATA4 regulatory loop, solely characterized here in a breast cancer cell model, has any role in mature heart before trying to elucidate these apparently opposite outcomes.
Considering the major role played by ERBB2 and GATA4 in the development of cardiovascular system (26, 51), our results provide some new clues to further investigate the molecular basis of trastuzumab cardiotoxicity. The complex transcriptional regulation of the ERBB2 gene and the transcriptional regulatory loop that associates this epidermal growth factor receptor and the cardiac-specific transcription factor GATA4 may indeed interfere with trastuzumab therapy. A precise and complete definition of these regulatory mechanisms is required for better understanding and fighting resistance to treatments targeting ERBB2 as well as limiting their cardiotoxicity.
Materials and Methods
Cell Lines and Breast Carcinoma Samples
The nononcogenic human primary mammary epithelium cells HME- (Table 2) . Twelve breast carcinoma samples were ERBB2 positive, whereas 5 samples were ERBB2 negative according to these criteria.
Plasmids and Transient Transfection Experiments
The ERBB2 reporter vectors containing promoter fragments of increasing sizes (13, 33) and GATA4 expression vector (34) were kindly provided by Dr. Rosita Winkler (Molecular Oncology Laboratory, University of Liege) and Dr. Walter L. ) were seeded in six-well plates (Falcon 3046; BD Biosciences) and treated with a FuGENE/DNA ratio of 3 AL/2 Ag for 48 h in complete medium. Sample (1 Ag) of each reporter construct was cotransfected with 0.4 Ag Renilla plasmid (pTK-RL; Promega) and 0.6 Ag pUC19. Cells were harvested and lysed and luciferase activities were measured according to the manufacturer's instructions (dual luciferase reporter gene assay kit; Promega). ERBB2 reporter vector activity was calculated as the ratio of firefly luciferase activity to Renilla luciferase activity and then expressed for each construct as the ratio to the minimal ERBB2 promoter vector (p215). GATA4 expression vector (0-0.2 Ag) was cotransfected with 1 Ag sample of each reporter construct, 0.4 Ag pTK-RL, 0.3 Ag pUC19, and 0.3 to 0.1 Ag pNF-nB-Luc. Transfections were done in triplicate and repeated at least in three independent experiments.
RNAi Assay
Three 25-mer duplex siRNA to target ERBB2 and GATA4, respectively, were obtained from a commercial source (Stealth select RNAi; Invitrogen). All siRNA duplexes (10 nmol/L) and Stealth RNAi Negative Control duplexes were transfected to 3 Â 10 5 cells in six-well plates by Lipofectamine RNAiMAX (Invitrogen) for 48 h at 37jC in a CO 2 incubator according to the manufacturer's instructions. Gene knockdown was confirmed by qRT-PCR and immunoblotting. Inhibition effects were observed from all siRNA duplexes and the siRNA that induced the highest inhibition were used in three independent experiments.
qRT-PCR
Total RNA from cell lines was extracted using RNeasy Micro Kit (Qiagen) according to the manufacturer's protocol. Total RNA from tumor samples was extracted as described previously (53) . RNA was quantified using a Nanodrop 1000 spectrophotometer device. RT-PCR was done using SuperScript II reverse transcriptase (Invitrogen) and random hexamer primers. DNA was quantified using LC FastStart DNA Master SYBR Green I and read with a Light Cycler 2 instrument (Roche Diagnostics) according to the manufacturer's instructions. The primers used for qRT-PCR analysis are listed in Table 3 . The precise amount of total cDNA added to each reaction mix and its quality are both generally difficult to assess. Therefore, the relative expression level of the gene of interest was computed with respect to the internal standard TBP to normalize for variations in RNA quality and the amount of input cDNA. Threshold cycles (Ct) were determined for quantification of the input target number.
For comparison between different cell lines and tumor samples, the target gene expression level (ERBB2 or GATA4) in each cell line and tumor samples was normalized using a calibrator RNA sample extracted from the HME-1 cell line. For RNAi assay, the RGE was calculated as a percentage of the measured mRNA level in cells transfected with target siRNA compared with cells transfected with matched control siRNA. Data were normalized against the TBP signal and the 2 -DDCt method was used to calculate the relative expression level of a given gene (54) .
Immunoblotting
For immunoblotting, 10 5 BT-474 cells were lysed in 10 AL lysis buffer [25 mmol/L Tris (pH 7.9), 1% (w/v) SDS, 1 mmol/L DTT] and fractionated on a 7.5% SDS-polyacrylamide gel and electrotransferred to a polyvinylidene fluoride membrane. Specific polypeptides were revealed with the rabbit polyclonal anti-ERBB2 (Santa Cruz Biotechnology), mouse monoclonal anti-GATA4 (Santa Cruz Biotechnology) at a dilution of 1:200 in TBS-Tween 20 containing 5% nonfat milk, and mouse monoclonal anti-h-tubulin (Abcam) at a dilution of 1:1,000 in TBS-Tween 20 containing 5% bovine serum albumin and then reacted with secondary antibodies at a dilution of 1:10 4 in the same buffer.
Chromatin Immunoprecipitation Assay
The chromatin immunoprecipitation assay was done using the Chromatin Immunoprecipitation Assay kit (Upstate). In brief, 2 Â 10 6 BT-474 cells were treated by 1% formaldehyde for 15 min at 37jC, and the cross-linking reaction was stopped by the addition of 125 mmol/L glycine incubating 10 min at room temperature. Cells were rinsed twice with ice-cold 1Â PBS containing protease inhibitors (Complete Protease Inhibitor Cocktail; Roche Diagnostics), scraped, and collected. After centrifugation, the cell pellet was lysed 10 min on ice in SDS lysis buffer supplemented with protease inhibitor cocktail. The chromatin was sheared by sonication to an average DNA length of 200 to 1,000 bp using a Sonics ultrasonic processor (750 W). The sonicated chromatin supernatant was diluted with Dilution Buffer containing protease inhibitor cocktail and subjected to a 30 min preclearing by incubation with salmon sperm DNA/protein A agarose-50% slurry beads at 4jC under rotation. The beads were pelleted, and the precleared chromatin supernatant was immunoprecipitated with 3 Ag of either a matched nonimmune IgG control (mouse IgG 2a ; BD Pharmingen) or a specific antibody (mouse monoclonal anti-GATA4; Santa Cruz Biotechnology) at 4jC overnight under rotation. Immunocomplexes were collected by 1 h incubation with salmon sperm DNA/protein A agarose-50% slurry at 4jC under rotation. Complexes were washed once, sequentially, in a lowsalt buffer, high-salt buffer, and low LiCl buffer and twice in TE buffer. The antibody-protein-DNA complexes were eluted twice in 250 AL elution buffer (0.1 mol/L NaHCO 3 , 1% SDS) by medium power vortexing and rotation for 15 min at room temperature. The combined eluates as well as the input sample (1% of the amount used in the immunoprecipitation procedure) were cross-link reversed by heating at least 4 h at 65jC in the presence of 200 mmol/L NaCl. After proteinase K digestion, the DNA fragments were extracted using phenol/chloroform and ethanol precipitated. qRT-PCR using LC FastStart DNA Master SYBR Green I and Light Cycler 2 instrument (Roche Diagnostics) and semiquantitative PCR were done with selected primer pairs (Table 1) . For each experimental sample, the amount of target and endogenous reference was determined from a standard curve. The standard curve was constructed with 4-fold serial dilutions of input from the BT-474. The results from specific antibodies were reported to that observed in the corresponding IgG samples. A region between the GAPDH and CNAP1 genes was used as the negative control to standardize the results from all the conserved regions (ChIP-It protocol; Active Motif).
EMSA
Complementary oligonucleotides carrying a GATA motif related to the GATA4-specific binding site of the IL-5 gene promoter (36) 
Site-Directed Mutagenesis
Site-directed mutagenesis was carried out using QuikChange II Site-Directed Mutagenesis Kit (Stratagene). PCR was done in ERBB2 reporter vectors using following primers: forward 5 ¶-gatgcaagctccccaggaaagtttagtcgacaacctgagacttaaaagggtgt-3 ¶ and reverse 5 ¶-acacccttttaagtctcaggttgtcgactaaactttcctggggagcttgcatc-3 ¶. PCR products were digested by DpnI restriction enzyme and transformed in XL1-Blue supercompetent cells. Mutated ERBB2 luciferase reporter vectors were confirmed by sequencing.
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